How can MyTrack™ Myeloma support more informed, shared decision-making?

Adapting therapy to a patient's individual needs and wishes is always an individual decision. It comes with uncertainties and, particularly with our current standard-of-care testing, the uncertainties are actually considerable. MyTrack™ Myeloma is designed to reduce these uncertainties and have much better, more precise information to discuss with the patient whether a planned treatment break is the right choice for the patient. This suite of tests is really designed to identify the optimal candidates for a planned treatment break, but also to guide the physicians and the patient together through a planned treatment break, should that decision be made, to keep it safe and to track the disease to a high level of sensitivity, allowing potential restarting of treatment if this is needed.